PDCD7抗体;PDCD7 Antibody—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Western blot analysis using ACADM mouse mAb against Hela (1), HepG2 (2),Jurkat (3),Raji (4) and K562 (5) cell lysate.    

  
  

•  

   

     Immunofluorescence analysis of Hela cells using ACADM mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor- 555 phalloidin. Secondary antibody from Fisher (Cat#: 35503)    

  
  

•  

   

     Flow cytometric analysis of HL-60 cells using ACADM mouse mAb (green) and negative control (red).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human cervical carcinoma tissues using ACADM mouse mAb with DAB staining.    

  
  

The PDCD7 (Programmed Cell Death 7) protein, encoded by the *PDCD7* gene, is a lesser-studied member of the programmed cell death-related protein family, which is implicated in regulating apoptosis and cellular homeostasis. While its exact molecular mechanisms remain unclear, PDCD7 is believed to participate in mitochondrial function and stress response pathways. Studies suggest it may interact with other apoptosis regulators, such as Bcl-2 family proteins, to modulate cell survival or death under physiological or pathological conditions.

PDCD7 antibodies are immunological tools developed to detect, quantify, or inhibit the PDCD7 protein in experimental or clinical settings. These antibodies, often monoclonal or polyclonal, are utilized in techniques like Western blotting, immunohistochemistry, or flow cytometry to study PDCD7 expression patterns in tissues or cell lines. Emerging research links altered PDCD7 expression to diseases such as cancer, neurodegenerative disorders, and autoimmune conditions, though its role (pro-apoptotic or anti-apoptotic) appears context-dependent. For example, in certain cancers, PDCD7 downregulation correlates with tumor progression, suggesting a tumor-suppressive function.

Current PDCD7 antibody research focuses on clarifying its biological roles and therapeutic potential. Challenges include validating antibody specificity due to limited characterization of PDCD7 isoforms and cross-reactivity risks. Further studies are needed to explore PDCD7 as a biomarker or target for precision therapies.